James F. Emigh is VP & Corporate Development at ACURA PHARMACEUTICALS, INC (ACUR). They have made 3 open-market trades across 1 company since 2011, most recently 2021-02-24.
CIK 0001107934
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $71K since 2011, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ACUR | 474,042 | $294K |
Shares reported on the most recent Form 4, priced at the 2021-02-26 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.